

A close-up portrait of a woman with long dark hair and a light blue jacket. She has a white transdermal patch on her right cheek. The background is a collage of white pills with diagonal lines, overlaid on a brick wall texture. A dark grey banner with white text is positioned across the top of the image.

DON'T JUST MEDICATE. ACTIVATE.

**TRANSFORM TREATMENT. TRANSFORM LIVES.
TRANSFORM YOUR PRACTICE.**

 **NeuroStar**[®]
Advanced Therapy

The Time is Now for a Life-Changing MDD Treatment

3 out of 5 MDD patients treated through medication are underserved¹



The STAR*D trial demonstrates that as patients move through medication trials:²⁻⁵

- Likelihood of achieving remission declines from 27.5% with first-line treatment to 6.9% with fourth-line treatment
- Likelihood of discontinuation rises from 8.6% with first-line treatment to 41.4% with fourth-line treatment

LACK OF EFFICACY

INTOLERABLE SIDE EFFECTS

"Medication worked for a while but then it didn't. The side effects were intolerable - I felt numb, I felt disconnected from myself and my family . . . from my world. I couldn't sleep, I gained weight."

-Martha Rhodes, NeuroStar[®] Patient

Transform MDD Treatment With NeuroStar® Advanced Therapy

NeuroStar can help your patients achieve long-term remission



- #1 TMS choice of doctors
- Proven safe & effective through largest clinical set:
 - 11 studies, 900 patients, 23 publications⁶
- 68% of patients maintained response and 45% maintained remission in 12 month-follow up⁷
- No systemic side effects
- APA-recommended treatment
- Over 1 million treatments already delivered
- Covered by most insurance plans

"The most exciting thing . . . is that we now have a tool that is non-invasive, doesn't have [drug] side effects, that may be more effective . . . for treating the depressed patient who . . . has not responded to medication."


–Lee Ann Kelley, MD, NeuroStar Provider

The most common side effect is pain or discomfort at or near the treatment site.⁶

In long-term follow-up 36.2% of patients received NeuroStar Advanced Therapy reintroduction (average of 16 treatments). Long-term durability of effect has not been established in a randomized, controlled trial. Trial design used physician-directed standard of care.⁷

Transform Lives – Help Your Patients Reach Remission and Stay There


Proven Efficacy Across a Range of Treatment Resistance⁸



Only TMS With Durability Over 12 Months⁷

68% maintained response


45% maintained remission



36.2% of patients received NeuroStar[®] Advanced Therapy reintroduction (average of 16 treatments). Long-term durability of effect has not been established in a randomized, controlled trial. Trial design used physician-directed standard of care.⁷

In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical trial version of the NeuroStar TMS System were four times more likely to achieve remission compared to patients receiving sham treatment ($P = 0.0173$; odds ratio = 4.05).⁹

Transform Lives With Proven Safety and Tolerability



Adverse events occurring at an incidence >5% and 2x the rate of placebo treatment.^{6, 10}

MEDICATIONS: Other adverse events are nervousness, weakness, abnormal ejaculation, constipation, anxiety, impotence, diarrhea, increased appetite, dizziness, sweating, decreased appetite, tremor, drowsiness, decreased sexual interest, headache/migraine, blurred vision, and treatment discontinuation side effects.

NEUROSTAR: Other adverse events are eye pain, toothache, muscle twitching, facial pain, and pain of skin.


NeuroStar[®] Advanced Therapy Treats Right at the Source Every Time

Transcranial Magnetic Stimulation (TMS) uses a highly focused pulsed magnetic field to stimulate cortical neurons

- Targeted stimulation of the left prefrontal cortex modulates deeper brain regions involved in mood regulation¹²
- Directly depolarizes cortical neurons and modulates neurotransmitter release
- Increases cerebral blood flow and glucose metabolism
- These changes can result in improved mood



Brain Activity is Reduced in Depression



Source: Mark George, M. D. Biological Psychiatry Branch Division of Intramural Research Programs, NIMH 1993¹³


NeuroStar[®] Advanced Therapy: Precision Treatment in Under 19 Minutes*

Only NeuroStar proprietary technology can deliver on precision therapy.



NEW! HIGH-PERFORMANCE CONTOURED COIL **Provides Unique Benefits:**

- Fast, convenient <19-minute treatment – up to 16 patients/day
- Customized patient-specific fit to establish appropriate dosing
- Provides assurance you are delivering the exact dosage to the right location



CONTACT SENSING:

- Real-time feedback – monitors for continuous contact on scalp throughout treatment
- Alerts clinician if coil loses contact or becomes misaligned
- Ensures patients receive full prescribed dose



3-D LASER POSITIONING SYSTEM:

- Laser-guided system ensures repeatable and accurate treatment

"I become very emotional . . . when I talk about certain patients because of the dramatic change from despair . . . to . . . the life that they were meant to live."

–Marie Surpris, DO, NeuroStar Provider

*Some patients may require longer treatment.





NEW! TRAKSTAR™ CLOUD DATA MANAGEMENT:

Secure data access anytime, anywhere

- **MANAGES** treatment protocols for consistent, optimized dosing
- **TRACKS** treatment history and outcomes automatically from NeuroStar®
- **REPORTS** customized easily – patient records, reimbursement claims, referring physician communication



NeuroStar® Advanced Therapy Transform Your Practice With Ease for Long-Term Success

With over 775 installations and counting, NeuroStar provides the most comprehensive TMS practice integration in the industry.

A CLINICAL & PRACTICE CONSULTANT LEADS THE TEAM TO:

- Operationalize Quickly
- Navigate Reimbursement
- Deliver 99% System Uptime
- Achieve Clinical Success
- Grow Your Practice



Operationalize Quickly

- Customizable Practice Success Program
- Physician Locator brings patients to your practice



Navigate Reimbursement



Access to most experienced specialists in industry – >30,000 benefits investigations



Deliver 99% System Uptime
 24-hr service guarantee –
 largest local tech service team



Achieve Clinical Success
 On-site clinical training and
 24/7 support hotline



Grow Your Practice
 Highest investment in category – bringing patients to you

Only NeuroStar[®] Advanced Therapy Drives Patient Interest

Advertising & Public Relations



- Highest investment in the category to drive awareness – 10X more than all TMS manufacturers combined

Physician Locator & Appointment Scheduler

- Physician Locator Tool on NeuroStar website drives patients to your practice
- 750,000 web searches & growing; has generated over 90,000 Physician Locator searches

Marketing & Educational Resources

- Direct mail, print, web banners, social media posts
- Comprehensive patient-friendly educational materials
- **COMING SUMMER 2017: *My NeuroStar Marketing Resource Center*** portal is turnkey – access high-quality NeuroStar-branded marketing materials you can customize with your logo to promote your practice



Take the Next Step With NeuroStar® Advanced Therapy

TRANSFORM TREATMENT

- Only FDA-cleared TMS treatment <19 minutes
- Proprietary technology delivers a precision dose every time
- No systemic side effects

TRANSFORM PATIENT LIVES

- Largest clinical data set⁶ and only TMS with durability over 12 months⁷
- Improved patient-reported quality of life^{14,15}

TRANSFORM YOUR PRACTICE

- Full support team to quickly operationalize NeuroStar
- Breakthrough option for proven treatment and growing your practice
- NeuroStar marketing power brings patients to you




NeuroStar Advanced Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. The most common side effect is pain or discomfort at or near the treatment site.¹⁰

In a randomized controlled trial (Solvason, et al., 2014) and in a separate open-label, naturalistic study (Janicak, 2013), NeuroStar Advanced Therapy showed statistically significant improvement in patient-reported quality of life outcome measures.^{14,15}

NeuroStar[®] – the #1 TMS Choice of Doctors Nationwide

Over 1 Million Treatments Already Delivered in the US



CONSULTATION



MOTOR THRESHOLD



4-6 WEEK TREATMENT



RESPONSE/REMISSION[®]

Proven in Clinical Practice and the Lives of Patients*

"When I know that I can help an individual and that NeuroStar® has an efficacy, why wouldn't I give them the opportunity. . . . NeuroStar provides that opportunity."

-Kimberly Cress, MD, NeuroStar Provider

"We all deserve to have the best quality of life that we can make for ourselves. And we need to try every option possible to get there. NeuroStar is one of those options."

-Colleen, NeuroStar Patient

"NeuroStar is different from any other treatment that we psychiatrists have been able to provide to patients. . . . so many patients have recognized dramatic and consistent change."

-Marie Surpris, DO, NeuroStar Provider

"Choose to be happy. Choose to do something to fight the battle. Don't just say it's never gonna be any better. You know, try things. Try . . . NeuroStar."

-Carol, NeuroStar Patient

"We all have patients who still suffer with depression regardless of the variety of medicines . . . or other treatments. . . . NeuroStar TMS has let me get more people better because I have another tool."

-Todd Hutton, MD, NeuroStar Provider

"It was actually two and a half to three weeks into treatment where I felt some relief. I felt kind of a lift. . . . I felt like I had a future, finally. And I'd never felt like that before. NeuroStar gave me my life back."

-Kristi, NeuroStar Patient

*Individual results may vary.

INDICATION

NeuroStar® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

IMPORTANT INFORMATION

The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. NeuroStar Advanced Therapy is available by prescription only. NeuroStar Advanced Therapy should not be used with patients who have non-removable conductive metal in or near the head.

In an NIMH-funded independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were four times more likely to achieve remission compared to patients receiving sham treatment ($P = 0.0173$; odds ratio = 4.05).⁹

Please visit NeuroStar.com for full safety and prescribing information.

References: **1.** Kessler RC, et al. (2003) *JAMA*, 289(23):3095-3105; 2012 U.S. Census Bureau. **2.** Trivedi MH, et al. (2006) Evaluation of Outcomes with Citalopram for Depression Using Measurement-Based Care in STAR*D Implications for Clinical Practice. *Am J Psychiatry*, 163(1):28-40. **3.** Rush AJ, et al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *Am J Psychiatry*, 163(11):1905-1917. **4.** Fava M, et al. (2006) A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A Star*D Report. *Am J Psychiatry*, 163(7):1161-1172. **5.** McGrath PJ, et al. (2006) Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. *Am J Psychiatry*, 163(9):1531-1541. **6.** Neuronetics, Inc., Data on file. **7.** Dunner DL, et al. (2014) A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. *J Clin Psychiatry*, 75(12):1394-1401. **8.** Carpenter LL, et al. (2012) Transcranial Magnetic Stimulation (TMS) for Major Depression: A Multisite, Naturalistic, Observational Study of Acute Treatment Outcomes in Clinical Practice. *Depression and Anxiety*, 29:587-596. **9.** George MS, et al. (2010) Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder: A Sham-Controlled Randomized Trial. *Arch Gen Psychiatry*, 67(5):507-516. **10.** Janicak PG, et al. (2008) Transcranial Magnetic Stimulation in the treatment of major depression: A comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. *Journal of Clinical Psychiatry*, 69(2):222-232. **11.** Rosenquist PB, et al. (2013) Left dorsolateral prefrontal transcranial magnetic stimulation (TMS): Sleep factor changes during treatment in patients with pharmacoresistant major depressive disorder. *Psychiatry Res*, 205(1-2):67-73. **12.** Liston C, et al. (2014) Default mode network mechanisms of transcranial magnetic stimulation in depression. *Biol Psychiatry*, 76(7):517-26. **13.** Source: Mark George, M. D. Biological Psychiatry Branch Division of Intramural Research Programs, NIMH 1993. **14.** Janicak PG, et al. (2013) Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice. *CNS Spectrums*, 18(6):322-32. **15.** Solvason HB, et al. (2014) Improvement in Quality of Life With Left Prefrontal Transcranial Magnetic Stimulation in Patients With Pharmacoresistant Major Depression: Acute and Six Month Outcomes, *Brain Stimulation*, 7(2):219-225.

